ReviewJournal of nanobiotechnology2019
Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.
Review in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Innovative Designs of Multimodal Imaging Based on Radionuclide, Quantum, and Cargo-Loaded Nanoplatform Emitters Towards Enhanced Energy-Matter Interactions for Photonics and Bioassays.Materials (Basel, Switzerland) · 2026Review
- Design of a bispecific peptide-nanozyme conjugate for cancer immunotherapy.Cell reports. Medicine · 2026Article
- Tumor Microenvironment Onmyoji: Cytokines with Dual Protumor and Antitumor Roles.Cancer communications (London, England) · 2026Review
- Synthesis, radiolabeling, and biodistribution evaluation of novel hyperbranched polyglycerols-based radiotracers for targeting PSMA in prostate cancer.Iranian journal of basic medical sciences · 2026Article
- Balloon-Occluded Hepatic Radioembolization with Yttrium-90 (b-TARE) in Selected Patients with Unresectable Heterogeneous Hepatocellular Carcinoma (HCC): A Safe and Effective Approach to Improve the Dose Rate.Diagnostics (Basel, Switzerland) · 2025Article
- In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.Journal of nanobiotechnology · 2025Review
- Utilizing nanomaterials for cancer treatment and diagnosis: an overview.Discover nano · 2024Review
- Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.Precision radiation oncology · 2024Review
- Recent progress in quantitative analysis of self-assembled peptides.Exploration (Beijing, China) · 2024Review
- Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model.NPJ systems biology and applications · 2024Article
- Molecular Eye: A System for Precise Diagnosis and Treatment of Major Clinical Diseases Based on Molecular Probe Technology.Chemical & biomedical imaging · 2024Review
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Nanomaterials in Targeting Cancer Cells with Nanotherapeutics: Transitioning Towards Responsive Systems.Current pharmaceutical design · 2024Review
- Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review.Pharmaceutics · 2023Review
- Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy.Pharmaceutics · 2023Article
- Radiolabeled Liposomes for Nuclear Imaging Probes.Molecules (Basel, Switzerland) · 2023Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- PET Oncological Radiopharmaceuticals: Current Status and Perspectives.Molecules (Basel, Switzerland) · 2022Review
- The present and future of immunocytokines for cancer treatment.Cellular and molecular life sciences : CMLS · 2022Review
- Preclinical Evaluation of hnRNPA2B1 Antibody in Human Triple-Negative Breast Cancer MDA-MB-231 Cells via PET Imaging.Pharmaceutics · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Radiopharmaceuticals have proven to be effective agents, since they can be successfully applied for both diagnostics and therapy. Effective application of relevant radionuclides in pre-clinical and clinical studies depends on the choice of a sufficient delivery platform. Herein, we provide a comprehensive review on the most relevant aspects in radionuclide delivery using the most employed carrier systems, including, (i) monoclonal antibodies and their fragments, (ii) organic and (iii) inorganic nanoparticles, and (iv) microspheres. This review offers an extensive analysis of radionuclide delivery systems, the approaches of their modification and radiolabeling strategies with the further prospects of their implementation in multimodal imaging and disease curing. Finally, the comparative outlook on the carriers and radionuclide choice, as well as on the targeting efficiency of the developed systems is discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.